Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

748
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
748
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

279
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
279
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

389
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
389
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

433
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
433
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

797
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
797

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Prognostic Impact of Cardiorespiratory Fitness on Mortality in Diabetes Patients With and Without Left Ventricular Hypertrophy.

Reviews in cardiovascular medicine·2026
Same author

The Art of Estimating Cardiorespiratory Fitness.

Mayo Clinic proceedings·2026
Same author

Characteristics and Outcomes of Over 1 Million Veterans With Heart Failure Phenotyped Using Artificial Intelligence Approaches: the National DCVA-HF Registry.

Journal of cardiac failure·2026
Same author

Risk of a Dementia Diagnosis in Community-Dwelling Older Adults With Normal MMSE Scores in the United States.

American journal of medicine open·2026
Same author

Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.

European journal of heart failure·2026
Same author

Serum Magnesium and Outcomes in U.S. Veterans with Heart Failure.

The American journal of medicine·2026

Related Experiment Video

Updated: Feb 27, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K

NAFLD-NASH: An Under-Recognized Epidemic.

Joseph Jennings1,2, Charles Faselis3,4, Michael D Yao1,2,4

  • 1Gastroenterology/Hepatology, MedStar Georgetown University Hospital, Washington, DC, United States.

Current Vascular Pharmacology
|July 6, 2017
PubMed
Summary
This summary is machine-generated.

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent worldwide, linked to obesity and metabolic syndrome. This trend predicts significant future impacts on liver disease, cancer, and cardiovascular events.

Keywords:
NAFLDNASHmetabolic syndromeobesityprevalencesteatosis.

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.8K

Related Experiment Videos

Last Updated: Feb 27, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.8K

Area of Science:

  • Hepatology
  • Epidemiology
  • Metabolic Diseases

Background:

  • Nonalcoholic fatty liver disease (NAFLD), first identified in 1980, is a growing global health concern with largely unknown exact incidence and prevalence.
  • The condition is associated with risk factors including advanced age, male gender, obesity, and metabolic syndrome components.

Purpose of the Study:

  • To summarize the current understanding of nonalcoholic fatty liver disease (NAFLD) epidemiology and associated risk factors.
  • To highlight the projected increase in NAFLD and its significant public health implications.

Main Methods:

  • Review of epidemiological data on NAFLD prevalence and incidence.
  • Analysis of risk factors and demographic associations, including genetic predispositions like PNPLA3 polymorphisms.
  • Examination of the link between NAFLD and coronary atherosclerosis.

Main Results:

  • NAFLD prevalence is increasing globally, though regional variations exist.
  • Obesity, male gender, advanced age, and metabolic syndrome are key risk factors.
  • Hispanic populations exhibit higher NAFLD rates, potentially due to genetic factors such as PNPLA3 gene polymorphisms.

Conclusions:

  • The rising rates of obesity worldwide suggest a continued increase in NAFLD.
  • NAFLD poses substantial future risks for cirrhosis, hepatocellular carcinoma, liver transplantation, and cardiovascular events, affecting millions.
  • Further research into genetic and environmental factors is crucial for understanding and managing NAFLD prevalence.